Nephrocare Health Services Limited (NSE:NEPHROPLUS)

Market Cap	65.12B
Revenue (ttm)	10.53B +39.3%
Net Income	851.10M +26.8%
EPS	8.63 +7.7%
Shares Out	100.34M
PE Ratio	75.19
Forward PE	37.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	238,798
Open	661.95
Previous Close	659.75
Day's Range	636.85 - 662.00
52-Week Range	446.00 - 781.50
Beta	n/a
Analysts	Strong Buy
Price Target	847.50 (+30.6%)
Est. Earnings	Nov 6, 2026

About NSE:NEPHROPLUS

Nephrocare Health Services Limited provides dialysis healthcare services through a chain of kidney care clinics and dialysis centers in India, Uzbekistan, Nepal, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. The company was incorporated in 2009 and is based in Hyderabad, India.

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 2009
• Employees: 2,294
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: NEPHROPLUS

Financial Performance

In fiscal year 2026, NSE:NEPHROPLUS's revenue was 9.99 billion, an increase of 32.16% compared to the previous year's 7.56 billion. Earnings were 768.40 million, an increase of 14.52%.

Analyst Summary

According to 4 analysts, the average rating for NEPHROPLUS stock is "Strong Buy." The 12-month stock price target is ₹847.50, which is an increase of 30.60% from the latest price.

Price Target

₹847.50

(30.60% upside)

Analyst Consensus: Strong Buy

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Oct 2, 2026

Data Sources Report a data error